Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 582 (ZNF582)
- Target
- ZNF582
- Molecular classification
- Transcription factor, Zinc finger protein family, KRAB-ZNF protein (contains KRAB [Krüppel-associated box] domain)
01
Overview
Zinc finger protein 582 is a protein-coding, nuclear transcription factor found in humans. It belongs to the Krüppel-type zinc finger protein family and contains both a KRAB domain and nine zinc-finger motifs. ZNF582 is involved in transcriptional regulation and nucleic acid binding. It is highly methylated in invasive cancer tissues, especially cervical cancer, where its silencing is associated with worse outcomes. While not yet fully characterized, it is suggested to act as a tumor suppressor and is used as a diagnostic biomarker for cervical neoplasia. Hypermethylation and silencing of ZNF582 are linked to progression and poor prognosis in multiple tumor types, including renal cell carcinoma, oral cancer, and nasopharyngeal carcinoma. ZNF582 expression can be regulated by DNA methylation, and its methylation pattern is a valuable biomarker for the detection and monitoring of cervical cancer.
- Other names
- FLJ30927
02
Mechanism of action
Drugs or interventions that affect DNA methylation can regulate ZNF582 expression. Diagnostic agents/hybrid tests combining HPV DNA detection and ZNF582 methylation monitoring for cervical cancer.
03
Biological functions
Transcriptional regulationNucleic acid bindingRegulation of cell proliferation and cell cycle (suggested by family association)DNA damage response (KRAB-ZNF family suggestion)Neoplastic transformation (possible role inferred from suppression and methylation in cancer)
04
Disease associations
Cancer (cervical, vulva, oral, nasopharyngeal, renal cell, and possibly leukemia)Chronic cervicitisMetastasis (regulation of adhesion molecules, aggressive progression)
05
Safety considerations
No notable safety concerns or therapeutic challenges are associated with ZNF582 targeting itself, since current use is in diagnostics and methylation analysis.Clinical targeting for therapy is not yet established; off-target effects of methylation-modifying drugs are possible but not specific for ZNF582.
06
Interacting drugs
No specific drugs directly targeting ZNF582 are reported in current literature or databases.
1 more in the full profile.
07
Biomarkers
ZNF582 methylation status (for cervical neoplasia, especially CIN3+ and squamous cell carcinoma)Proposed as a molecular screening biomarker for early cervical cancer
Beyond the preview
Go deeper on Zinc finger protein 582 (ZNF582).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zinc finger protein 582 (ZNF582).